Topics

Articles

There are now 11 cell/gene therapies targeting Covid-19 in development

Ed Schoonveld’s compilation on pricing strategies gets updated for the 2020s

Company pitches a mfr-payer-provider-patient collaboration for drug pricing

Acquisitions jump BMS and Takeda into Top 10; Amgen and Gilead fall out

Guidance for companies starting out on the commercialization path

The PBMs’ new trend toward controlling the flow of funds for patient support is raising questions

Former J&J executive will be the organization’s third-ever leader

Milken Institute survey finds nearly 300 therapies and vaccines